CPT code 86481 – Tuberculosis interferon gamma release assay, T-cell enumeration

Key takeaways

CPT code 86481 covers the IGRA that counts gamma interferon-producing T-cells in a cell suspension, which in practice means T-SPOT.TB.

QuantiFERON-TB Gold Plus measures gamma interferon in plasma, so it bills under 86480, not 86481.

The two codes split by assay method, not by antigen or tube count, and NCCI bars billing both on one date of service.

ICD-10 Z11.1 is the standard screening pairing. Use an LTBI history or confirmed TB code only when the chart supports it.

86481 is reimbursed under the Medicare Clinical Laboratory Fee Schedule, not the Physician Fee Schedule.

Claims software such as Pabau checks each 86481 claim for missing or invalid details before it reaches the clearinghouse.

CPT code 86481: Official descriptor and procedure description

CPT code 86481 describes: Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension. It sits in the Immunology subsection (86000-86849) of the Pathology and Laboratory chapter.

The key phrase is “enumeration of gamma interferon-producing T-cells in cell suspension.” The lab isolates peripheral blood mononuclear cells (PBMCs) from the sample, counts them, and exposes them to TB antigens. It then counts each T-cell that releases gamma interferon, using an ELISpot method. That is how T-SPOT.TB works, and the AMA created 86481 for it, effective January 1, 2011.

Neither 86480 nor 86481 mentions antigens or tubes in its descriptor. The codes split by assay method, so the number of antigen tubes or panels never decides which one you bill.

Assays that map to CPT 86480 and 86481

Note on lab method changes: The code follows the method the lab runs, not the brand name on the order. In 2021, the University of Michigan lab moved its QuantiFERON billing to 86481 after a method change. Treat that as a lab-specific exception, and confirm the method in the performing lab’s test catalog before you assign either code.

CPT 86480 vs 86481: Key differences

A common coding error in TB IGRA billing is assigning 86481 to a QuantiFERON test. The two codes describe different lab methods, and payers audit for the mismatch. The decision comes down to one question about what the lab measured.

Most US labs run QuantiFERON-TB Gold Plus, so 86480 is the IGRA code most outpatient and occupational health claims need. Reserve 86481 for T-SPOT.TB or another lab-confirmed T-cell enumeration method. If your EHR maps QuantiFERON orders to 86481, update the order set.

CPT 86481 vs PPD / TST skin test codes

Blood-based IGRAs and tuberculin skin tests (TSTs) serve the same clinical purpose but bill under completely different code families. They are not interchangeable on the same date of service.

86580 covers the intradermal PPD (Mantoux) test. Reading the result 48 to 72 hours later has no separate CPT code.

CDC and USPSTF guidelines indicate IGRA is preferred over TST in BCG-vaccinated individuals because prior BCG vaccination can cause false-positive TST results. That clinical preference does not automatically translate to payer coverage. Some commercial plans and Medicaid programs still require TST first and only cover IGRA on a step-edit basis.

ICD-10 codes to pair with CPT code 86481

Payers validate that the diagnosis code supports the medical necessity of the IGRA. Using Z11.1 correctly is the first line of defense against a CO-11 denial.

Verify each code against your MAC’s LCD covered-indication list before billing. Novitas, CGS, and Palmetto GBA each publish an LCD governing IGRA reimbursement, and covered diagnosis codes sometimes differ across contractors.

Medicare coverage and reimbursement for CPT code 86481

CPT code 86481 is reimbursed under the Medicare Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. Rates are set annually by CMS and differ between independent laboratory settings and hospital outpatient settings. Check the current-year rate in the CMS Clinical Laboratory Fee Schedule files before you quote expected reimbursement to a patient or payer.

National and local coverage determination (NCD / LCD) requirements

No standalone National Coverage Determination (NCD) governs 86481 at the federal level. Coverage is managed through Local Coverage Determinations issued by each MAC. Three key LCD families to know:

• Novitas Solutions (JH / JL jurisdictions): Covers 86481 for high-risk patient populations. Requires documentation of the clinical risk factor triggering the test.
• CGS Administrators (J15 jurisdiction): LCD-based coverage for LTBI screening. A policy update removed prior age floors, but verify the effective date and policy number directly with CGS.
• Palmetto GBA (J11 / J12 jurisdictions): Coverage aligned with CDC high-risk indications. Frequency limits may apply for serial testing.

When billing Medicare, pull the specific LCD in effect for your MAC jurisdiction and retain a copy in your billing records. LCD-based denials are almost always preventable with the right documentation on file at the time of service.

Prior authorization requirements by payer

Most traditional Medicare claims for CPT code 86481 do not require prior authorization. The picture is different for commercial plans and Medicare Advantage.

• Traditional Medicare (Parts A/B): No prior auth required. LCD-based coverage criteria apply at claim adjudication.
• Medicare Advantage plans: Authorization requirements vary by plan. Many MA plans follow traditional Medicare LCD criteria but add a preauthorization step for laboratory panels. Check the plan’s provider portal or call the plan’s lab services line before ordering.
• Commercial insurance: Large insurers (UnitedHealth, Aetna, Cigna, BlueCross) generally do not require prior auth for 86481 as a standalone LTBI screening test. Prior auth is more common when 86481 appears alongside immunosuppression workup panels or biologic-therapy initiation orders.
• Medicaid (state-by-state): Authorization requirements differ significantly. Some state Medicaid programs require TST first, followed by IGRA only if TST results are indeterminate or the patient cannot tolerate TST.

When prior auth is required, document the clinical risk factor, the order rationale, and any prior TST results in the authorization request. Turnaround for lab-service authorizations is typically 24-72 hours for non-urgent cases.

Documentation requirements for CPT code 86481

Strong documentation is the difference between a paid claim and a post-payment audit recoupment. For medical billing compliance, the chart note supporting CPT code 86481 must contain all of the following before the claim goes out.

• Clinical indication: The specific risk factor that justifies testing. Examples include healthcare worker exposure, HIV-positive status, planned immunosuppressive therapy, foreign birth in a high-prevalence country, or close contact with an active TB case.
• Ordering provider: Name, NPI, and signature on the order, with the date of the order matching the date of service.
• Test result documented: The IGRA result (positive, negative, indeterminate) must appear in the patient record linked to the claim date. Include the lab’s reference range and report date.
• Diagnosis linkage: The ICD-10 code on the claim must be traceable to a documented condition or screening encounter in the chart note. Z11.1 standing alone without any documented risk indicator is an audit red flag.
• For LTBI treatment follow-up: Document the prior LTBI diagnosis date, prior treatment, and the clinical reason for repeat testing.

Occupational health settings handle high volumes of IGRA orders. A clean claim submission requires that batch orders include individual patient-level documentation, not a single group notation. Each patient record must stand alone under audit.

Common claim denial reasons for CPT code 86481 and how to fix them

These are the denial patterns billing staff see most often on 86481 claims, along with the corrective action and resubmission approach. For deeper context on managing these across your practice, see denial management workflows and the reference on medical billing denial codes.

Bundling rules and unbundling edits for CPT code 86481

The National Correct Coding Initiative (NCCI) publishes quarterly procedure-to-procedure (PTP) edit tables that govern which codes can be reported together. For CPT code 86481, the most important edit pairs it with 86480. The practitioner PTP table lists 86481 as column 1 and 86480 as column 2, as mutually exclusive procedures. Its modifier indicator is 0, so no modifier can override it. Both codes answer the same clinical question using different lab methods.

• 86480 and 86481, same DOS: Mutually exclusive, with no modifier override. Do not bill both. Bill the one code that matches the assay method on the lab report.
• 86359 (T-cell total count): Listed as a column 2 code to 86481. The edit’s modifier indicator is 1, so a modifier applies only when a separately ordered, documented T-cell count was performed.
• 87116 (mycobacteria culture): May be billed with 86481 when a sputum or specimen culture is performed in addition to the blood IGRA. These are distinct services on distinct specimens. No modifier is required when the medical record clearly documents both orders and both results.
• Comprehensive metabolic or infectious disease panels: 86481 is sometimes ordered as part of a broader panel, such as a pre-biologic therapy workup. If the payer bundles the IGRA into the panel payment, Modifier 59 (distinct procedural service) or Modifier XU (unusual non-overlapping service) may support separate payment. The chart note must document a separate clinical justification for the IGRA.

Always verify NCCI edits against the current quarterly table. The edits above come from the Q4 2026 Medicare practitioner PTP table (version 32.3). Edit assignments change between quarters, so a coder working from last year’s table can bill a pair that is now barred.

How to bill CPT 86481: Step-by-step

A clean 86481 claim follows a predictable workflow. Claims most often fail at step 2 (wrong code assigned) or step 4 (diagnosis not on the LCD list).

1. Verify the assay method: Check the performing lab’s test catalog or report. An ELISA-based QuantiFERON test (Gold or Gold Plus) points to 86480. A T-SPOT.TB ELISpot T-cell count points to 86481.
2. Assign the matching code: Use 86481 only for a T-cell enumeration assay such as T-SPOT.TB. Document the lab name and assay name in the order or result note.
3. Select the correct ICD-10: Start with Z11.1 for screening. Add a secondary code for the specific risk factor if your MAC’s LCD requires it (e.g., Z20.1 for contact with TB case).
4. Check LCD covered indications: Look up your MAC’s active LCD. Confirm the patient’s clinical scenario appears on the covered-indication list. If it does not, document why the IGRA is clinically necessary and consider an ABN for Medicare patients.
5. Check prior authorization: For Medicare Advantage or commercial plans requiring auth, submit the request before the test is performed where possible.
6. Submit the claim: Bill to the patient’s lab benefit (not the physician benefit). Include the rendering lab’s NPI and CLIA number. Run the claim through claims software for practices that flags missing or invalid details before it reaches the clearinghouse.
7. Monitor the ERA / remittance: Review the 835 electronic remittance advice for CARC codes on any denial. Route CO-11 and CO-96 denials to a clinical staff member who can pull the chart note for appeal.

How Pabau reduces denials on CPT 86481 claims

Each denial in this guide starts upstream in medical billing, before the claim leaves the practice. A QuantiFERON order lands under 86481, a Z11.1 claim goes out without a risk factor, or a Medicare Advantage plan wanted an authorization nobody requested.

Pabau, the practice management platform we build, raises the claim from the patient’s invoice and submits it as a CMS-1500 through Claim.MD. Its claim validation scrubs each claim for missing or invalid details before it leaves Pabau. Prior authorizations are stored as a case and attached at booking, so the authorization code follows the appointment onto the claim.

When a claim comes back rejected, Pabau flags it as Needs action and links straight to the field that needs correcting. Payments settle from the electronic remittance advice (ERA) file, so your team works the denials instead of matching remittances by hand. No software can promise the payer’s decision, but the coding and data errors you control get caught first.

Catch 86481 coding errors before submission

Pabau’s claim validation checks each TB test claim for missing or invalid details before it reaches Claim.MD. Rejected claims show the reason and the field to fix, so each correction takes seconds.

Book a demo

Conclusion

Code the method, not the brand name. Before any IGRA claim goes out, confirm what the lab ran, then bill 86481 for T-SPOT.TB and 86480 for QuantiFERON.

The harder habit is documentation. A Z11.1 claim with no recorded risk factor may pay today and still fail an LCD audit later. Write the risk factor into the chart note at the visit, when it takes one sentence.

Book a demo to see how Pabau checks TB test claims for coding and diagnosis errors before they reach the payer.

Continue your research

Need to understand how clearinghouse validation reduces claim errors? Claim.MD clearinghouse overview covers how real-time eligibility and 837P validation work for lab claims.

Want a framework for tracking denial patterns across your billing team? Revenue cycle management fundamentals explains how to build a denial-trend dashboard and reduce preventable write-offs.

Billing for other lab immunology codes alongside 86481? Superbill construction guide walks through how to structure multi-code lab claims accurately.

Frequently asked questions